Beyond Air (XAIR) Q4 2026 Earnings Call Transcript

Beyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, with a 90% customer renewal rate. The company is focusing resources on its LungFit PH nitric oxide delivery system and expects FDA approval of its second-generation device in late 2026. Management projects 2027 revenue of $16-18 million (110%+ growth) assuming Gen 2 launch, with expanded market access through three major GPO agreements covering ~7,000 hospitals. The company reduced net cash burn by 56% and achieved gross profit of $300,000 in fiscal 2026.